Literature DB >> 10495091

Tolerance to the antinociceptive effect of morphine microinjections into the ventral but not lateral-dorsal periaqueductal gray of the rat.

V Tortorici1, C S Robbins, M M Morgan.   

Abstract

Tolerance to the antinociceptive effect of morphine is mediated at least in part by morphine's action within the periaqueductal gray (PAG). The objective of the present study was to determine whether both ventral and lateral-dorsal PAG regions contribute to the development of tolerance. It was found that the antinociceptive efficacy of microinjecting morphine (5 microg/0.4 microl) into the ventral but not the lateral-dorsal PAG diminished with successive injections. Control experiments indicated that this decrease was caused by tolerance to morphine and was not a result of cell death caused by repeated microinjections or habituation from repeated behavioral testing. The finding of greater susceptibility of the ventral compared with the lateral-dorsal PAG to the development of tolerance adds to a growing literature distinguishing antinociception from these two regions.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10495091     DOI: 10.1037//0735-7044.113.4.833

Source DB:  PubMed          Journal:  Behav Neurosci        ISSN: 0735-7044            Impact factor:   1.912


  30 in total

1.  Extracellular signal-regulated kinase 1/2 activation counteracts morphine tolerance in the periaqueductal gray of the rat.

Authors:  Tara A Macey; Erin N Bobeck; Deborah M Hegarty; Sue A Aicher; Susan L Ingram; Michael M Morgan
Journal:  J Pharmacol Exp Ther       Date:  2009-08-14       Impact factor: 4.030

Review 2.  Inflammatory mediators of opioid tolerance: Implications for dependency and addiction.

Authors:  Lori N Eidson; Anne Z Murphy
Journal:  Peptides       Date:  2019-03-16       Impact factor: 3.750

3.  Lack of Antinociceptive Cross-Tolerance With Co-Administration of Morphine and Fentanyl Into the Periaqueductal Gray of Male Sprague-Dawley Rats.

Authors:  Erin N Bobeck; Shauna M Schoo; Susan L Ingram; Michael M Morgan
Journal:  J Pain       Date:  2019-03-07       Impact factor: 5.820

4.  Enhanced antinociception with repeated microinjections of apomorphine into the periaqueductal gray of male and female rats.

Authors:  Shauna M Schoo; Erin N Bobeck; Michael M Morgan
Journal:  Behav Pharmacol       Date:  2018-04       Impact factor: 2.293

5.  Periaqueductal gray neuroplasticity following chronic morphine varies with age: role of oxidative stress.

Authors:  D Bajic; C B Berde; K G Commons
Journal:  Neuroscience       Date:  2012-09-19       Impact factor: 3.590

6.  Glutamate modulation of antinociception, but not tolerance, produced by morphine microinjection into the periaqueductal gray of the rat.

Authors:  Michael M Morgan; Erin N Bobeck; Susan L Ingram
Journal:  Brain Res       Date:  2009-08-05       Impact factor: 3.252

7.  Relative contribution of the dorsal raphe nucleus and ventrolateral periaqueductal gray to morphine antinociception and tolerance in the rat.

Authors:  Kyle N Campion; Kimber A Saville; Michael M Morgan
Journal:  Eur J Neurosci       Date:  2016-09-14       Impact factor: 3.386

8.  The periaqueductal gray contributes to bidirectional enhancement of antinociception between morphine and cannabinoids.

Authors:  Adrianne R Wilson-Poe; Edvinas Pocius; Melissa Herschbach; Michael M Morgan
Journal:  Pharmacol Biochem Behav       Date:  2012-10-10       Impact factor: 3.533

9.  Transcutaneous electrical nerve stimulation at both high and low frequencies activates ventrolateral periaqueductal grey to decrease mechanical hyperalgesia in arthritic rats.

Authors:  J M DeSantana; L F S Da Silva; M A De Resende; K A Sluka
Journal:  Neuroscience       Date:  2009-07-02       Impact factor: 3.590

10.  Sexually dimorphic activation of the periaqueductal gray-rostral ventromedial medullary circuit during the development of tolerance to morphine in the rat.

Authors:  Dayna R Loyd; Michael M Morgan; Anne Z Murphy
Journal:  Eur J Neurosci       Date:  2008-03       Impact factor: 3.386

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.